When it is quiet – “almost too quiet” – in movies, it is a sign that something is about to go wrong for the good guys. This holds true for the genes that protect against lung cancer, as researchers at the University of Toledo in Toledo, Ohio, have learned. They identified a panel of 15 genes that could serve to predict cancer; if enough of their collective activity becomes quiet – almost too quiet -- it could mean they are being suppressed by other factors in the cell, a step that may lead to cancer.
According to lead researcher, James C. Willey, M.D., a test for these genes, in normal cells sampled via bronchoscopy, could serve as a technique to identify those individuals genetically at risk for lung cancer. In a study of 49 subjects, Dr. Willey and his colleagues were able to correctly identify the individuals with cancer 96 percent of the time. Dr. Willey presents the team’s findings today in Atlanta, Georgia at the American Association for Cancer Research’s second International Conference on Molecular Diagnostics in Cancer Therapeutic Development.
“Smoking causes about 90 percent of all lung cancer cases, yet only about 10 to 15 percent of heavy smokers will develop lung cancer,” said Dr. Willey, an associate professor of medicine and molecular biology at the University of Toledo’s College of Medicine. “We are looking for new techniques that will allow us to pick out the 10 to 15 percent of individuals at highest risk for lung cancer from the enormous pool of current and former smokers.”
While advances in screening tools like high resolution coaxial tomography (HRCT) enable increasingly effective early detection of lung cancer, scanning all present or former heavy smokers is problematic and costly when, due to genetic makeup, 85 to 90 percent of them are at low risk despite smoking history, Dr. Willey said. Therefore, Willey believes that a screen to identify the 10 to 15 percent of high risk individuals should increase the accuracy of further HRCT screening. “In America alone, there are more than 40 million present or former heavy smoking individuals,” Dr. Willey said.
To determine which genes are active in lung cancer, Dr. Willey and his colleagues look for levels of messenger RNA transcripts -- instructions copied from DNA that direct cells to create specific proteins. Previously, the researchers had published findings demonstrating that genes responsible for protecting lung cells from damage caused by cigarette smoke or environmental toxins are sub-optimally regulated in the normal lung cells of individuals who develop lung cancer. In this study, Dr. Willey and his colleagues put their theories to the clinical test by measuring transcript abundance (TA) of 15 genes that encode protective antioxidant and DNA repair proteins in lung airway cells taken from 25 people with lung cancer and 24 people without the disease.
Their previous research allowed them to determine the threshold levels of TA for each gene – the point at which the amount of mRNA transcripts would indicate a tendency toward cancer. In this study, they used the threshold levels as a basis to assign a value of one or zero to each of the targeted genes for an individual subject, with “zero” indicating normal TA.
If the sum total of a subject’s target genes was greater than or equal to seven, the genes could collectively serve as a biomarker for lung cancer, the researchers found. Their results yielded one false negative and seven false positives among the 49 individuals assessed. According to Dr. Willey, they believe that a positive result in a subject without lung cancer may not actually be false positive, but rather could mean that the person is at an increased risk for lung cancer, which might arise later.
These results justify a larger, prospective study to determine whether this biomarker will be useful in predicting risk for lung cancer in current and former smokers. “Overall, the study showed a high degree of accuracy for picking out lung cancer patients,” said Dr. Willey.
Source: American Association for Cancer Research
Explore further: New prognostic test for breast cancer could improve patient treatment